CN113092771A - Application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases - Google Patents
Application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases Download PDFInfo
- Publication number
- CN113092771A CN113092771A CN201911334036.2A CN201911334036A CN113092771A CN 113092771 A CN113092771 A CN 113092771A CN 201911334036 A CN201911334036 A CN 201911334036A CN 113092771 A CN113092771 A CN 113092771A
- Authority
- CN
- China
- Prior art keywords
- glycoprotein
- urine
- allergic diseases
- alpha
- allergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides urine Alpha-1B-glycoprotein and application of polypeptide fragments thereof, in particular to application of urine Alpha-1B-glycoprotein and polypeptide fragments thereof in preparation of a preparation for detecting allergic diseases. The allergic diseases are also called allergic diseases, and typical allergic diseases (allergic diseases) include allergic rhinitis, bronchial asthma, allergic dermatitis, eczema, allergic conjunctivitis, anaphylactic shock, and the like, and are hereinafter collectively referred to as allergic diseases. The research proves that compared with a healthy human group (normal control), the expression of the urine alpha-1B-glycoprotein and the polypeptide fragment thereof is increased in the allergic disease patient group, and the method can be used for auxiliary diagnosis of the allergic disease patient. The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and utilizes the urine specimen to detect the urine alpha-1B-glycoprotein and the polypeptide fragment thereof.
Description
Technical Field
The invention relates to a new application of urine alpha-1B-glycoprotein and a polypeptide fragment thereof, in particular to an application of urine alpha-1B-glycoprotein and a polypeptide fragment thereof in monitoring allergic diseases.
Background
Allergic diseases are also called allergic diseases, and typical allergic diseases comprise allergic rhinitis, bronchial asthma, allergic dermatitis, eczema, allergic conjunctivitis, anaphylactic shock and the like. According to the statistics of the world health organization, the number of allergic people is huge in the world, and about one third of people suffer from allergic diseases. In recent years, due to rapid change of life style of people, remarkable improvement of industrialization degree and remarkable aggravation of air pollution, the incidence rate of allergic diseases rises year by year, serious allergic diseases even endanger life, and the problem becomes a global public health focus at present.
Currently, clinical auxiliary examination of allergic diseases mainly includes Skin Prick Test (SPT), serum sIgE detection and the like, but SPT patients have poor pain compliance and are easily affected by drugs, and the risk of systemic anaphylaxis can be increased, so that the SPT test is not suitable for severe allergic constitution and children and old people. The detection of sIgE is also not a non-invasive one, and often requires repeated blood drawing of the patient. In order to improve the life quality and compliance of patients with allergic diseases and relieve the pain of repeated blood collection and prick tests, the urine protein or polypeptide research is expected to realize the diagnosis of the allergic diseases assisted by painless, convenient, quick and easily repeated urine detection and also lay a foundation for the further research of the urine polypeptide detection kit.
alpha-1B-glycoprotein (A1 BG) is an approximately 63kDa plasma glycoprotein that contains a single peptide stretch of 474 amino acid residues and 4 glucosamine oligosaccharides. The A1BG domain analysis shows that it is composed of 1 signal peptide region and 4 mechanisms and components of C-2 immunoglobulin, belongs to the immunoglobulin super family members, and is an important glycoprotein involved in the cell regeneration process. Research has shown that alpha-1B-glycoprotein shows expression difference in acute myocardial infarction, endometriosis, lung cancer, diabetes and other diseases. In this study, the expression of alpha-1B-glycoprotein in urine of patients with allergic diseases is up-regulated compared with that of healthy groups.
Compared with the common clinical blood sample, the urine can be collected in a non-invasive, continuous and large amount; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a longer time. In order to alleviate the pain of the patients with allergic diseases in the multiple blood sampling and prick test, the test is expected to be helpful for the diagnosis of the allergic diseases by detecting urine protein or polypeptide on the basis of the previous methodology.
Disclosure of Invention
The invention aims to provide application of urine alpha-1B-glycoprotein and polypeptide fragments thereof in preparation of preparations for detecting allergic diseases.
Preferably, the amino acid sequence of the urine alpha-1B-glycoprotein is shown in SEQ ID NO.1 (MSMLVVFLLL WGVTWGPVTE AAIFYETQPS LWAESESLLK PLANVTLTCQ AHLETPDFQL FKNGVAQEPV HLDSPAIKHQ FLLTGDTQGR YRCRSGLSTG WTQLSKLLEL TGPKSLPAPW LSMAPVSWIT PGLKTTAVCR GVLRGVTFLL RREGDHEFLE VPEAQEDVEA TFPVHQPGNY SCSYRTDGEG ALSEPSATVT IEELAAPPPP VLMHHGESSQ VLHPGNKVTL TCVAPLSGVD FQLRRGEKEL LVPRSSTSPD RIFFHLNAVA LGDGGHYTCR YRLHDNQNGW SGDSAPVELI LSDETLPAPE FSPEPESGRA LRLRCLAPLE GARFALVRED RGGRRVHRFQ SPAGTEALFE LHNISVADSA NYSCVYVDLK PPFGGSAPSE RLELHVDGPP PRPQLRATWS GAVLAGRDAV LRCEGPIPDV TFELLREGET KAVKTVRTPG AAANLELIFV GPQHAGNYRC RYRSWVPHTF ESELSDPVEL LVAES); or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
Preferably, the alpha-1B-glycoprotein and polypeptide fragments thereof are from urinary exosomes.
Preferably, the urine alpha-1B-glycoprotein and polypeptide fragments thereof are highly expressed in patients with allergic diseases.
Preferably, the preparation is a kit for detecting the urine alpha-1B-glycoprotein and polypeptide fragments thereof of patients with allergic diseases.
Preferably, the kit comprises one or more of an aptamer antibody or antibody fragment capable of specifically binding to alpha-1B-glycoprotein and polypeptide fragments thereof.
Preferably, the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and.
Preferably, the standard comprises an alpha-1B-glycoprotein standard, a humanized tag antibody standard; preferably, the quality control product comprises: alpha-1B-glycoprotein quality control product and humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose, and has similar functions.
The inventor firstly collects urine samples of healthy people and patients with allergic diseases, centrifuges the urine samples, takes supernate, and purifies and separates the urine samples by using weak cation exchange magnetic beads. Uniformly mixing 1 mu l of sample and 10 mu l of matrix, taking 1 mu l of point on an Anchorchip target plate, ionizing the sample, carrying out mass spectrometry, and collecting data within the range of 1000-10000Da to obtain a mass spectrometry polypeptide diagram consisting of protein peaks with different mass-to-charge ratios. All mass spectra of healthy persons and groups of allergic diseases were analyzed using the BioExplorer analysis software to screen for differential polypeptides. Then, the inventor carries out matrix-assisted laser desorption ionization time-of-flight mass spectrometry identification on the differential polypeptide with statistical significance, obtains the alpha-1B-glycoprotein with differential expression by searching a database, and the alpha-1B-glycoprotein is highly expressed in urine of allergic diseases compared with a healthy human group.
Compared with healthy people, the alpha-1B-glycoprotein and the polypeptide fragment thereof are high in expression in urine of patients with allergic diseases and have better consistency with clinical diagnosis. Therefore, the detection of the urine alpha-1B-glycoprotein and the polypeptide fragment thereof can be used for detection or auxiliary diagnosis of allergic diseases.
The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and utilizes the urine specimen to detect the urine alpha-1B-glycoprotein and the polypeptide fragment thereof.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
FIG. 1 is a graph of the peak intensity distribution of alpha-1B-glycoprotein in urine of healthy persons and patients with allergic diseases.
FIG. 2 is a scattergram of α -1B-glycoprotein expression in urine samples of healthy persons and patients with allergic diseases.
FIG. 3 is a ROC curve of alpha-1B-glycoprotein expression in urine of patients with allergic diseases.
Detailed Description
Example 1Collection and processing of urine specimens
60 patients with allergic diseases are collected in clinic diagnosis of the Beijing century jar hospital affiliated to the university of capital medical science, and the age of the patients is 23-58 years as a group of the allergic diseases (allergic diseases). 60 healthy examiners of the physical examination center of the Beijing century bed hospital affiliated to the university of capital medical science were collected as a control group. After urine collection, 400 Xg centrifugation for 5min, supernatant was collected and split charged and frozen at-80 ℃. A comparison of the clinical characteristics of these subjects is shown in table 1.
Table 1 general clinical data of patients in allergic disease (allergic disease) group and control group are compared.
Example 2Magnetic bead purification and urine polypeptide screening
And (3) enriching the polypeptide in the urine by using weak cation exchange magnetic beads, and analyzing the polypeptide spectrum in the urine by using a matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS). Mu.l of the eluate was mixed with 10. mu.l of matrix (0.3% of. alpha. -cyano-4-hydroxycinnamic acid, HCCA) and 1. mu.l of the spot was applied to an Anchorchip target plate and dried at room temperature. The specimen is ionized by nitrogen laser irradiation and calibrated before further mass spectrometry of the specimen. After calibrating the instrument with the standard, the sample is detected, data in the range of 1-10kDa are collected, and a mass spectrogram consisting of protein peaks with different mass-to-charge ratios is obtained. For each MALDI target, a total of 400 laser shots were performed. The 8 different positions of each target point were irradiated 50 times each, and the average value represents one specimen. Thereby obtaining all samplesThe polypeptide map. Three biological replicates were performed per sample. All spectra obtained from the urine samples were analyzed using the BioExplorer software. The software removes the base line from the mass spectrogram and standardizes the mass spectrogram, the mass range is 1000-10000Da, the signal-to-noise ratio (S/N) is more than 5, the mass drift does not exceed 0.1 percent, and the mass spectrum is measured in the mass spectrum measuring device>Peaks detected in 80% of the samples were considered informative and were screened for differential polypeptides. The polypeptide peaks of mass to charge ratio (m/z) 1066.5 were statistically different between the 2 groups (m/z)P<0.01) and the distribution of the average peak intensities thereof is shown in fig. 1.
Example 3Identification and analysis of differential Polypeptides
From the sample tube, 20 ul was taken for LC-MS/MS analysis. An EASY-nLC1000 HPLC system was used for the separation. Liquid phase a was 0.1% formic acid in acetonitrile (2% acetonitrile) and liquid phase B was 0.1% formic acid in acetonitrile (98% acetonitrile). The chromatographic spray needle is PN: FS 360-20-10-N-20-C12. Samples were separated by capillary HPLC and analyzed by Q-exact mass spectrometer (Thermo). The ion source voltage is 3.5kv, the analysis time is 120min, and the scanning range of the parent ion is 300-2000 m/z. The mass-to-charge ratios of the polypeptides and polypeptide fragments were collected by collecting 20 fragments (MS 2scan, HCD) after each complete scan. At M/Z200, the MS1 resolution was 70,000, and the MS2 resolution was 17,500. Data analysis software Peaks8.5 (Bioinformatics Solutions Inc.) was used for the search. The search database was the ipi human database (v 3.45). The parent ion error was set to 10 ppm, the fragment ion error was set to 0.02 Da, and the digestion mode was non-digestion.
The differentially expressed polypeptide peak of mass to charge (m/z) 1087.6 was retrieved in the database and identified as alpha-1B-glycoprotein.
Compared with healthy people, the alpha-1B-glycoprotein is highly expressed in urine of patients with allergic diseases, and as shown in figure 2, the expression of the alpha-1B-glycoprotein in urine of healthy people and patients with allergic diseases is significantly different.
Further, the inventor detects a polypeptide peak value with a mass-to-charge ratio (m/z) of 1087.6 in urine of 60 patients with allergic diseases and 60 healthy people, establishes a ROC curve with an area under the curve of 0.657, and reflects that the sensitivity and specificity of alpha-1B-glycoprotein are better as shown in FIG. 3.
Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Sequence listing
<110> Beijing century bed Hospital affiliated to capital medical university (Beijing railway general Hospital)
<120> application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases
<130> 19PA1BG-CN
<140> 19PA1BG-CN
<141> 2019-12-06
<160> 1
<170> SIPOSequenceListing 1.0
<210> 2
<211> 495
<212> PRT
<213> Human, Urine
<400> 2
Met Ser Met Leu Val Val Phe Leu Leu Leu Trp Gly Val Thr Trp Gly
1 5 10 15
Pro Val Thr Glu Ala Ala Ile Phe Tyr Glu Thr Gln Pro Ser Leu Trp
20 25 30
Ala Glu Ser Glu Ser Leu Leu Lys Pro Leu Ala Asn Val Thr Leu Thr
35 40 45
Cys Gln Ala His Leu Glu Thr Pro Asp Phe Gln Leu Phe Lys Asn Gly
50 55 60
Val Ala Gln Glu Pro Val His Leu Asp Ser Pro Ala Ile Lys His Gln
65 70 75 80
Phe Leu Leu Thr Gly Asp Thr Gln Gly Arg Tyr Arg Cys Arg Ser Gly
85 90 95
Leu Ser Thr Gly Trp Thr Gln Leu Ser Lys Leu Leu Glu Leu Thr Gly
100 105 110
Pro Lys Ser Leu Pro Ala Pro Trp Leu Ser Met Ala Pro Val Ser Trp
115 120 125
Ile Thr Pro Gly Leu Lys Thr Thr Ala Val Cys Arg Gly Val Leu Arg
130 135 140
Gly Val Thr Phe Leu Leu Arg Arg Glu Gly Asp His Glu Phe Leu Glu
145 150 155 160
Val Pro Glu Ala Gln Glu Asp Val Glu Ala Thr Phe Pro Val His Gln
165 170 175
Pro Gly Asn Tyr Ser Cys Ser Tyr Arg Thr Asp Gly Glu Gly Ala Leu
180 185 190
Ser Glu Pro Ser Ala Thr Val Thr Ile Glu Glu Leu Ala Ala Pro Pro
195 200 205
Pro Pro Val Leu Met His His Gly Glu Ser Ser Gln Val Leu His Pro
210 215 220
Gly Asn Lys Val Thr Leu Thr Cys Val Ala Pro Leu Ser Gly Val Asp
225 230 235 240
Phe Gln Leu Arg Arg Gly Glu Lys Glu Leu Leu Val Pro Arg Ser Ser
245 250 255
Thr Ser Pro Asp Arg Ile Phe Phe His Leu Asn Ala Val Ala Leu Gly
260 265 270
Asp Gly Gly His Tyr Thr Cys Arg Tyr Arg Leu His Asp Asn Gln Asn
275 280 285
Gly Trp Ser Gly Asp Ser Ala Pro Val Glu Leu Ile Leu Ser Asp Glu
290 295 300
Thr Leu Pro Ala Pro Glu Phe Ser Pro Glu Pro Glu Ser Gly Arg Ala
305 310 315 320
Leu Arg Leu Arg Cys Leu Ala Pro Leu Glu Gly Ala Arg Phe Ala Leu
325 330 335
Val Arg Glu Asp Arg Gly Gly Arg Arg Val His Arg Phe Gln Ser Pro
340 345 350
Ala Gly Thr Glu Ala Leu Phe Glu Leu His Asn Ile Ser Val Ala Asp
355 360 365
Ser Ala Asn Tyr Ser Cys Val Tyr Val Asp Leu Lys Pro Pro Phe Gly
370 375 380
Gly Ser Ala Pro Ser Glu Arg Leu Glu Leu His Val Asp Gly Pro Pro
385 390 395 400
Pro Arg Pro Gln Leu Arg Ala Thr Trp Ser Gly Ala Val Leu Ala Gly
405 410 415
Arg Asp Ala Val Leu Arg Cys Glu Gly Pro Ile Pro Asp Val Thr Phe
420 425 430
Glu Leu Leu Arg Glu Gly Glu Thr Lys Ala Val Lys Thr Val Arg Thr
435 440 445
Pro Gly Ala Ala Ala Asn Leu Glu Leu Ile Phe Val Gly Pro Gln His
450 455 460
Ala Gly Asn Tyr Arg Cys Arg Tyr Arg Ser Trp Val Pro His Thr Phe
465 470 475 480
Glu Ser Glu Leu Ser Asp Pro Val Glu Leu Leu Val Ala Glu Ser
485 490 495
Claims (9)
1. Application of urine alpha-1B-glycoprotein and polypeptide fragments thereof in preparing preparations for detecting allergic diseases.
2. The use of claim 1, wherein the amino acid sequence of said urinary α -1B-glycoprotein is set forth in SEQ ID No. 1; or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
3. The use of claim 1, wherein said α -1B-glycoprotein and polypeptide fragments thereof are derived from urine.
4. The use according to claim 1, wherein said urinary α -1B-glycoprotein and polypeptide fragments thereof are highly expressed in patients with allergic diseases.
5. The use of claim 1, wherein the preparation is a kit for detecting alpha-1B-glycoprotein from urine of patients with allergic diseases and polypeptide fragments thereof.
6. The use of claim 5, wherein the kit comprises one or more of an aptamer antibody or antibody fragment capable of specifically binding to α -1B-glycoprotein and polypeptide fragments thereof.
7. The use according to claim 5, wherein the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and.
8. The use of claim 7, wherein the standard comprises an alpha-1B-glycoprotein standard, a humanized tag antibody standard; preferably, the quality control product comprises: alpha-1B-glycoprotein quality control product and humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
9. The use of claim 8, wherein the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911334036.2A CN113092771A (en) | 2019-12-23 | 2019-12-23 | Application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911334036.2A CN113092771A (en) | 2019-12-23 | 2019-12-23 | Application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113092771A true CN113092771A (en) | 2021-07-09 |
Family
ID=76662793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911334036.2A Pending CN113092771A (en) | 2019-12-23 | 2019-12-23 | Application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113092771A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300756A (en) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | Polypeptide-human alpha-1B-glucoprotein 12 and polynucleotide for coding this polypeptide |
| CN1609616A (en) * | 2003-10-03 | 2005-04-27 | 霍夫曼-拉罗奇有限公司 | Specific markers for diabetes |
| CN1795387A (en) * | 2003-03-25 | 2006-06-28 | 普罗特奥格尼克斯公司 | Proteomic analysis of biological fluids |
| US20090215636A1 (en) * | 2005-05-25 | 2009-08-27 | Krizman David B | Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations |
| US20140294843A1 (en) * | 2011-05-12 | 2014-10-02 | Temple University Of The Commonwealth System Of Higher Education | Diagnosis and treatment of copd |
| CN104704364A (en) * | 2012-06-15 | 2015-06-10 | 韦恩州立大学 | Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome |
-
2019
- 2019-12-23 CN CN201911334036.2A patent/CN113092771A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300756A (en) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | Polypeptide-human alpha-1B-glucoprotein 12 and polynucleotide for coding this polypeptide |
| CN1795387A (en) * | 2003-03-25 | 2006-06-28 | 普罗特奥格尼克斯公司 | Proteomic analysis of biological fluids |
| CN1609616A (en) * | 2003-10-03 | 2005-04-27 | 霍夫曼-拉罗奇有限公司 | Specific markers for diabetes |
| US20090215636A1 (en) * | 2005-05-25 | 2009-08-27 | Krizman David B | Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations |
| US20140294843A1 (en) * | 2011-05-12 | 2014-10-02 | Temple University Of The Commonwealth System Of Higher Education | Diagnosis and treatment of copd |
| CN104704364A (en) * | 2012-06-15 | 2015-06-10 | 韦恩州立大学 | Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome |
Non-Patent Citations (1)
| Title |
|---|
| AMRIT SINGH等: "Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge", 《PROTEOMICS CLIN. APPL.》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2463318A1 (en) | Methods and apparatuses for analyzing biological samples by mass spectrometry | |
| CN102323246B (en) | One group for detecting the characteristic protein of pulmonary carcinoma | |
| CN108020669B (en) | Application of urinary osteopontin and polypeptide fragment thereof in lung adenocarcinoma | |
| CN113092768A (en) | Application of urine keratin, II type cytoskeleton 1 and polypeptide fragment thereof in allergic diseases | |
| CN101153872B (en) | Novel reagent kit for detecting and estimating critical patients and method thereof | |
| CN113092771A (en) | Application of urine alpha-1B-glycoprotein and polypeptide fragment thereof in allergic diseases | |
| CN114280202B (en) | Biomarker for diagnosing cadmium poisoning and application thereof | |
| CN113092769A (en) | Application of urine complement C4-A and polypeptide fragment thereof in allergic diseases | |
| CN113092770A (en) | Application of urine albumin and polypeptide fragment thereof in allergic diseases | |
| CN113092773A (en) | Application of urine alpha-trypsin inhibitor heavy chain H4 and polypeptide fragment thereof in allergic diseases | |
| CN113092756A (en) | Application of urine prothrombin and polypeptide fragment thereof in allergic diseases | |
| CN113092772A (en) | Application of urine cadherin subgroup SA-2 and polypeptide fragment thereof in allergic diseases | |
| CN113495147A (en) | Application of urine alpha 2-macroglobulin and polypeptide fragment thereof in gestational diabetes | |
| CN113495148A (en) | Application of urine hemagglutinin protein and polypeptide fragment thereof in gestational diabetes | |
| CN101201355A (en) | Immunity group mass spectrometric detection individuation knubble biological flag as well as curative effect reagent box and method | |
| CN112924682B (en) | Application of urine fibrinogen alpha chain protein and polypeptide fragment thereof in normal pregnancy | |
| CN114487402A (en) | Urine non-secretory ribonuclease protein and application of polypeptide fragment thereof in gestational diabetes | |
| CN114252607A (en) | Application of urine V-ATPASE subunit S1 and polypeptide fragment thereof in allergic diseases | |
| CN112924681B (en) | Application of urine KRT10 protein and polypeptide fragment thereof in normal pregnancy | |
| CN114487431A (en) | Application of urine alpha-2-HS-glycoprotein and polypeptide fragment thereof in gestational diabetes | |
| CN112904012B (en) | Application of urine IGKC protein and polypeptide fragment thereof in normal pregnancy or gestational diabetes | |
| CN113495149A (en) | Application of urine alpha 1-microglobulin and polypeptide fragment thereof in gestational diabetes | |
| CN114252627A (en) | Application of urine hepcidin and polypeptide fragment thereof in allergic diseases | |
| CN112881689B (en) | Application of urine blood coagulation factor IX protein and polypeptide fragment thereof in normal pregnancy or gestational diabetes | |
| CN114252625A (en) | Application of urine hypertrophy/stem cell growth factor receptor and polypeptide fragment thereof in allergic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210709 |
|
| WD01 | Invention patent application deemed withdrawn after publication |